On this page
IKBKB
inhibitor of nuclear factor kappa B kinase subunit beta
IKBKB is located on the short (p) arm of chromosome 8, at band 8p11.21. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 8 in the library →Available at Jeen Health
Clinical tests that include this
Overview
IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) is located on chromosome 8 and produces IKK-beta, a central regulator of immune function. The protein operates as part of a multi-subunit enzyme complex that transmits signals from cell-surface receptors to the nucleus, where genes controlling inflammation, cell survival, and immune responses are switched on. This signalling pathway is active in nearly all cell types and responds to diverse triggers including bacterial products, viral infection, inflammatory cytokines, and cellular stress. Disruptions to IKBKB function can affect immune competence and inflammatory regulation throughout the body.
What the gene does
IKK-beta functions as a serine-threonine protein kinase within the IKK complex, partnering with IKK-alpha and the regulatory subunit NEMO. When cells detect immune or stress signals, the IKK complex becomes activated and phosphorylates inhibitor proteins that normally trap NF-kappa-B transcription factors in the cytoplasm. Once these inhibitors are phosphorylated, they are marked for degradation, allowing NF-kappa-B dimers to enter the nucleus and activate hundreds of target genes involved in inflammation, antiviral defence, and cell survival. IKK-beta is particularly responsive to pro-inflammatory cytokines such as tumour necrosis factor and interleukin-1, making it the dominant catalytic subunit for inflammatory signalling. The enzyme also participates in developmental processes, including skeletal formation and skin differentiation, reflecting the pathway's broad biological importance beyond immunity.
Video: Genetics 101
Chromosome location
IKBKB is positioned at chromosomal band 8p11.21 on the short arm of chromosome 8. This region contains multiple genes involved in cellular signalling and regulation. The precise exon structure and transcript variants of IKBKB contribute to the protein's regulatory flexibility in different tissue contexts.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein.
Key variants
Genetic variants in IKBKB can alter the kinase's activity, stability, or interactions with regulatory partners. Because the NF-kappa-B pathway must be tightly controlled, both excessive and insufficient IKK-beta function can have clinical consequences. Variants may influence susceptibility to inflammatory conditions or affect immune responsiveness, though the inheritance pattern and penetrance of such changes can vary depending on the specific alteration and genetic background.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1705G>T | p.Glu569Ter | Pathogenic | ★★☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.607G>A | p.Val203Ile | Pathogenic | ★★☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.856C>T | p.Arg286Ter | Pathogenic | ★★☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
g.(?_42146132)_(42146266_?)del | - | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.1273C>T | p.Gln425Ter | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.1392C>A | p.Cys464Ter | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.1429C>T | p.Gln477Ter | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.1696C>T | p.Gln566Ter | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.1735C>T | p.Arg579Ter | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
c.1847_1848del | p.Val616fs | Pathogenic | ★☆☆☆ | Severe combined immunodeficiency due to IKK2 deficiency |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Whilst IKBKB is not currently associated with well-defined Mendelian disorders in routine clinical databases, research continues to explore its involvement in complex inflammatory and immune-related phenotypes. Experimental studies have linked altered IKK-beta function to inflammatory bowel disease, autoimmune conditions, and certain cancers where chronic NF-kappa-B activation promotes tumour growth. The gene's central position in immune signalling means that dysregulation can have wide-ranging effects, though individual outcomes depend on the nature and location of the genetic change.
No disease links recorded for this gene in our reference set.
UK clinical status
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does the IKBKB gene do?
IKBKB encodes IKK-beta, a protein kinase that activates the NF-kappa-B signalling pathway in response to immune and inflammatory stimuli. This allows cells to coordinate responses to infection, stress, and developmental cues.
Where is IKBKB located in the genome?
The IKBKB gene is located at chromosomal band 8p11.21 on the short arm of chromosome 8.
Are there clinical tests for IKBKB variants in the UK?
IKBKB is not currently included on NHS Genomic Medicine Service gene panels for routine clinical testing. Research into the gene's role in disease continues, and clinical relevance may evolve as further evidence emerges.